Last updated on January 2019

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)


Brief description of study

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Clinical Study Identifier: NCT02628067

Contact Investigators or Research Sites near you

Start Over

Toll Free Number

Call for Information (Investigational Site 0018)
Duarte, CA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0202)
Los Angeles, CA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0006)
San Francisco, CA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0203)
Aurora, CO United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0015)
Orlando, FL United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0011)
Baltimore, MD United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0208)
Bethesda, MD United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0005)
Rockville, MD United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0207)
Boston, MA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0010)
Boston, MA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0209)
Boston, MA United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0206)
Rochester, MN United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0008)
New Brunswick, NJ United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0204)
Albuquerque, NM United States
  Connect »

Toll Free Number

Call for Information (Investigational Site 0004)
Houston, TX United States
  Connect »

Australian Medical Information Centre

Merck Sharp & Dohme
North Ryde, Australia
  Connect »

MSD Online

MSD Brasil
Sao Paulo, Brazil
  Connect »

Liliana Ferro

MDS Colombia SAS
Bogota, Colombia
  Connect »

Katrin Moeschlin

Merck Sharp & Dohme
Glostrup, Denmark
  Connect »

Valerie Bouchara

MSD France
Paris, France
  Connect »

German Medical Information Center

MSD Sharp & Dohme GmbH
Haar, Germany
  Connect »

Dan Goldstaub

Merck Sharp & Dohme Co. Ltd.
Hod Hasharon, Israel
  Connect »

Paola Chiaretta Fattore

MSD Italia S.r.l.
Rome, Italy
  Connect »

Japan Call Center

MSD K.K.
Chiyoda-Ku, Tokyo, Japan
  Connect »

TaeYoun Jo

MSD Korea LTD
Seoul, Korea, Republic of
  Connect »

Alexandra Barajas

MSD
Mexico City, Mexico
  Connect »

Arjan Ooms

Merck Sharp & Dohme BV
Haarlem, Netherlands
  Connect »

Katrin Moeschlin

MSD Norge A/S
Drammen, Norway
  Connect »

Georgina Arnold

Merck Sharp & Dohme (I.A.) Corporation
Makati, Philippines
  Connect »

Tatiana Serebriakova

Merck Sharp & Dohme IDEA, Inc.
Moscow, Russian Federation
  Connect »

Zoe Nell

MSD (Pty) LTD South Africa
Midrand, South Africa
  Connect »

Lourdes Lopez-Bravo

Merck Sharp and Dohme de Espana S.A.
Madrid, Spain
  Connect »

Keris Huang

Merck Sharp & Dohme (I.A.) Corp.
Taipei, Taiwan
  Connect »

Paul Duffy

Merck Sharp & Dohme Ltd.
Hoddesdon, United Kingdom
  Connect »

Toll Free Number

Call for Information (Investigational Site 0014)
Tampa, FL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.